DPP4 and posterior cortical atrophy: Linagliptin’s anti-metastatic properties demonstrated superior efficacy compared to doxorubicin in both wound healing (Figures 8A,B) and transwell migration assays (Figures 9A,B), suggesting that DPP4 inhibition may represent a promising strategy for preventing or treating metastatic PCa.